COVID-19 Clinical Guidelines–Vaccine
If we can assist your organization in the battle against COVID-19, whether or not you are a current member, please contact us today at clientservices@ecri.org.
British HIV Association guidelines on immunisation for adults with HIV: SARS-CoV-2 (COVID-19) 2021
Date: 2021
Developer: British HIV Association (BHIVA)
Guideline Focus
Use of SARS-CoV-2 immunisation in people with HIV
Patient Population
Adults with HIV
Major Interventions
- Choice of vaccine, including HIV- and non-HIV-related risk factors, schedule, and booster
- Guidance on immune response to vaccine, including risk factors and modified vaccine schedules
- Patient education on side effects, post-vaccination period, and continuing risk reduction
- Guidance on antibody testing, co-administration of SARS-CoV-2 vaccines with other vaccines, and passive immunisation with antibodies
- Deference of vaccine due to acute illness, including COVID-19 infection
Guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines. Version 1.1
Date: 2021 Nov 8
Developer: Cardiac Society of Australia and New Zealand (CSANZ)/Australian Government Department of Health/Royal Australian College of General Practitioners (RACGP)/Australian College of Remote and Rural Medicine (ACRRM)/Australasian College for Emergency Medicine (ACEM)
Guideline Focus
Myocarditis and pericarditis after mRNA COVID-19 vaccines
Patient Population
People with and without a history of chronic cardiovascular conditions
Major Interventions
- Use of mRNA vaccines (i.e., Comirnaty, Spikevax) based on age and risk of contraindications or severe illness from COVID-19
- Guidance on advice for people with a history of cardiac conditions and those who experience myocarditis/pericarditis
- Assessment of suspected myocarditis or pericarditis
- Guidance on management of myocarditis/pericarditis and follow-up
Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons: interim guidance
Date: 2021 Oct 26
Developer: World Health Organization (WHO)
Guideline Focus
Interim guidance on an extended primary series of COVID-19 vaccine, with an additional vaccine dose, for immunocompromised persons
Patient Population
Immunocompromised persons (IPCs)
Major Interventions
- Indications for extending primary COVID-19 vaccine series to include additional dose, including consideration of timing
Coadministration of seasonal inactivated influenza and COVID-19 vaccines: interim guidance
Date: 2021 Oct 21
Developer: World Health Organization (WHO)
Guideline Focus
Coadministration of seasonal inactivated influenza and COVID-19 vaccines
Patient Population
Individuals receiving both COVID-19 and influenza vaccines
Major Interventions
- Guidance on coadministration vaccination programmes, including injection placements
- Post-authorization monitoring and research
The Advisory Committee on Immunization Practices' interim recommendations for additional primary and booster doses of COVID-19 vaccines - United States, 2021
Date: 2021 Nov 5
Developer: Centers for Disease Control and Prevention (CDC)
Guideline Focus
Use of additional primary mRNA COVID-19 vaccine dose and COVID-19 vaccine booster dose
Patient Population
Immunocompromised persons aged ≥18 years who completed a COVID-19 vaccine primary series ≥28 days ago (Pfizer-BioNTech, Moderna) AND persons aged ≥18 years who completed a COVID-19 vaccine primary series ≥6 months ago (Pfizer-BioNTech, also includes patients ≥12 years, Moderna) or ≥2 months ago (Janssen)
Major Interventions
- Use of an additional primary or booster vaccination dose for the prevention of COVID-19
The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in children aged 5–11 years — United States, November 2021
Date: 2021 Nov 12
Developer: Centers for Disease Control and Prevention (CDC)
Guideline Focus
Use of Pfizer-BioNTech COVID-19 vaccine in children aged 5–11 years
Patient Population
Children aged 5–11 years
Major Interventions
- Use of Pfizer-BioNTech vaccine for the prevention of COVID-19